Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Centocor's Simponi Becomes First TNF Blocker To Escape REMS Duties

Executive Summary

FDA's release of Centocor from a Risk Evaluation and Mitigation Strategy for Simponi could signal a reprieve from the REMS regulatory burden for other tumor necrosis factor inhibitors as well.
Advertisement

Related Content

Eliminating MedGuide-Only REMS Merits PDUFA-Style Deadlines, PhRMA Says
Eliminating MedGuide-Only REMS Merits PDUFA-Style Deadlines, PhRMA Says
FDA Warns Again Of Rare Cancer Associated With TNF Blockers
FDA To Sponsors: Say Goodbye To MedGuide-Only REMS
QOL Medical’s Sucraid Is First To Lose Its REMS
TNF Blocker Fungal Infection: FDA Uses REMS For Relabeling, Education
TNF Blocker Fungal Infection: FDA Uses REMS For Relabeling, Education

Topics

Advertisement
UsernamePublicRestriction

Register

PS053342

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel